NCT04742504View on ClinicalTrials.gov

Interaction Between Benralizumab and Basophils in Eosinophilic Asthma

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

October 1, 2023

Study Completion Date

October 13, 2023

Conditions
Asthma; Eosinophilic
Interventions
BIOLOGICAL

BENRALIZUMAB

The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).

Trial Locations (1)

Unknown

Instituto Investigación FJD, Madrid

All Listed Sponsors
lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT04742504 - Interaction Between Benralizumab and Basophils in Eosinophilic Asthma | Biotech Hunter | Biotech Hunter